Hims & Hers Faces a Perfect Storm of Competition, Regulation, and Margin Pressure

Hims & Hers shares gain 4% on a Bank of America upgrade tied to FDA peptide regulation, but face competitive threats, insider selling, and margin erosion.

The telehealth sector’s high-flying darling is navigating a treacherous stretch. Hims & Hers Health saw its shares climb roughly 4% to around $30.56 on Monday, buoyed by a Bank of America analyst upgrade tied to shifting FDA attitudes on peptide regulation. But beneath that surface-level optimism, a tangle of competitive threats, insider selling, and margin erosion is testing investor patience.

The Regulatory Wildcard

The FDA’s evolving stance on peptides could prove transformative for Hims & Hers. The company operates its own peptide manufacturing facility in California and has built partnerships around GLP-1 products, including arrangements for active ingredients like semaglutide. Bank of America now views this infrastructure as a potential scaling advantage in the booming weight-management market. The market is paying close attention—over 243,000 options contracts changed hands recently, signaling heightened interest.

Yet the regulatory calendar carries a looming risk. The FDA is scheduled to rule on certain peptides at the end of July. That decision directly affects the compounded weight-loss injections that have been a major driver of Hims & Hers’ customer growth. A ban would strike at the heart of the business model.

Competition Heats Up on Multiple Fronts

The weight-loss injection market is becoming a battlefield. Digital health platform Ro has slashed its monthly fees in half, charging customers just $74—roughly half of what Hims & Hers demands for its subscription. Amazon has entered the fray through its One Medical subsidiary, launching its own weight-management program. Meanwhile, pharmaceutical heavyweights like Eli Lilly are making their drugs more directly accessible to patients, putting further pressure on intermediaries.

The competitive pressure extends beyond weight management. In Hims & Hers’ traditional hair-loss segment, biotech firm Veradermics reported positive Phase 2/3 data for its oral hair-loss pill VDPHL01 on Monday—potentially the first FDA approval of its kind in three decades. While Hims & Hers has been pivoting toward weight management, it remains active in the hair-loss market, and this development shifts the competitive landscape.

Margin Squeeze and Insider Signals

The growth story remains intact on the top line. Revenue jumped 28.4% to $617.82 million in the fourth quarter of 2025, and the company posted nearly 60% growth for the full year, reaching $2.35 billion. But profitability is taking a hit. The gross margin contracted by 500 basis points to 72%, reflecting the costs of scaling the business.

Adding to the pressure, the company carries roughly $1 billion in outstanding convertible notes. Management has guided for 2026 revenue between $2.7 billion and $2.9 billion, with adjusted EBITDA in the range of $300 million to $375 million. The long-term target remains at least $6.5 billion in revenue by 2030.

Insider activity is raising eyebrows. Chief Financial Officer Oluyemi Okupe sold nearly $1.5 million worth of shares in April, and Chief Legal Officer Soleil Boughton also reduced her holdings. Such moves ahead of earnings typically fuel unease among investors.

International Expansion as a Counterweight

Hims & Hers is pursuing geographic diversification to offset domestic headwinds. The acquisition of Eucalyptus opens the Australian and Japanese markets, bringing with it an annual recurring revenue stream of more than $450 million. This international push could help cushion the impact of price wars and regulatory uncertainty at home.

The Earnings Test

All eyes are on May 11, when the company reports first-quarter 2026 results. Analysts expect revenue of roughly $621 million, a modest sequential increase. But earnings per share are forecast to plunge to just $0.06, underscoring the margin challenge.

The options market is pricing in a swing of about 5.8 points around the earnings report—a sign that investors see the outcome as highly uncertain. The short interest stands at an unusually high 35%, reflecting deep skepticism.

JPMorgan maintains an "Overweight" rating, pointing to a new partnership with Novo Nordisk that could stabilize the drug supply chain. But with the stock trading at roughly $30, the market is demanding proof that the company can retain its millions of subscribers while defending its margins. If it fails, that $1 billion debt pile could become a much heavier burden.